Economic analysis of 15-valent and 20-valent pneumococcal conjugate vaccines among older adults in Ontario, Canada
Vaccinating older adults with PCV15/20 likely reduces burden of pneumococcal disease and would be cost-effective initially, but is expected to be less economically attractive in the longer term when herd immunity benefits from childhood vaccination programs are considered.
Authors
- Beate Sander (ORCID: https://orcid.org/0000-0003-2128-9133)
- Shaza A. Fadel (ORCID: https://orcid.org/0000-0002-2336-6254)
- Gebremedhin Beedemariam Gebretekle (ORCID: https://orcid.org/0000-0002-2485-505X)
- Stephen Mac (ORCID: https://orcid.org/0000-0003-4736-1770)
- Natasha S. Crowcroft (ORCID: https://orcid.org/0000-0002-6761-8783)
- Ryan O’Reilly (ORCID: https://orcid.org/0000-0003-0844-7352)
Institutions
- University Health Network (CA)
- University of Toronto (CA)
- Health Net (US)
- Public Health Ontario (CA)
Publication Details
- Journal
- Expert Review of Vaccines
- Published
- 2025-04-04
- DOI
- https://doi.org/10.1080/14760584.2025.2488495
- Citations
- 1
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 1.35